CAR-T cell therapy
In a new study, Mayo clinic hematologist Saad Kenderian and his team have developed a strategy that may improve the performance of chimeric antigen receptor (CAR) T cell (car-t cell) therapy in treating cancer.
"In CAR-T cell therapy, doctors take T cells from patients and genetically modify them to recognize and fight cancer," Dr. Reona Sakemura said. Once these genetically modified T cells are reinfused into the patient, they seek out and eventually kill the cancer cells.”
To improve the effectiveness of car-t cells in treating these cancers, Sakemura and his colleagues developed a strategy that combines car-t cell therapy with a drug that targets AXL. This protein is present on the surface of cancer and within the cancer microenvironment. This drug, called "TP-0903", not only kills cancer cells, but also enhances the potency of CAR-T cells to attack cancer cells, potentially reducing the toxicity associated with CAR-T cell therapy. While more research and clinical trials are needed, Sakemura said, "we believe that this combination could eventually be used as a new way to enhance the efficacy of CAR-T cell therapy and to treat other B-cell cancers."
At present, Our DLdevelop has some Elisa Kits about T-cells such as DL-NFATC2-Hu, DL-NFATC1-Mu. To get more information, you could contact our professional staff directly or directly to our website:
https://dldevelop.com/Research-reagent/dl-nfatc2-hu.html
https://dldevelop.com/Research-reagent/dl-nfatc1-mu.html
"In CAR-T cell therapy, doctors take T cells from patients and genetically modify them to recognize and fight cancer," Dr. Reona Sakemura said. Once these genetically modified T cells are reinfused into the patient, they seek out and eventually kill the cancer cells.”
To improve the effectiveness of car-t cells in treating these cancers, Sakemura and his colleagues developed a strategy that combines car-t cell therapy with a drug that targets AXL. This protein is present on the surface of cancer and within the cancer microenvironment. This drug, called "TP-0903", not only kills cancer cells, but also enhances the potency of CAR-T cells to attack cancer cells, potentially reducing the toxicity associated with CAR-T cell therapy. While more research and clinical trials are needed, Sakemura said, "we believe that this combination could eventually be used as a new way to enhance the efficacy of CAR-T cell therapy and to treat other B-cell cancers."
At present, Our DLdevelop has some Elisa Kits about T-cells such as DL-NFATC2-Hu, DL-NFATC1-Mu. To get more information, you could contact our professional staff directly or directly to our website:
https://dldevelop.com/Research-reagent/dl-nfatc2-hu.html
https://dldevelop.com/Research-reagent/dl-nfatc1-mu.html
